News Headlines Article

Two Studies Challenge Avastin’s Effectiveness Against a Rare Brain Cancer
New York Times

Two new studies have found that the widely used cancer drug Avastin does not prolong the lives of patients with a deadly form of brain cancer, raising questions about the role of the drug in treating that disease. The results, presented at a conference here this weekend, could lead the Food and Drug Administration to revoke Avastin’s approval for the treatment of the brain cancer, called glioblastoma, much as it did with the drug’s approval for breast cancer.